Proapoptotic Bcl-2 inhibitor as host directed therapy for pulmonary tuberculosis
Preprint
- 2 September 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue damage / fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68 + and CD11b + cells. Finally, positron emission tomography (PET) in live animals using novel, clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74) demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed using post-mortem studies. Our studies suggest that proapoptotic drugs such as navitoclax can improve pulmonary TB treatments, and should be evaluated in clinical trials.Keywords
All Related Versions
- Version 1, 2024-09-02, Research Square
- Published version: Nature Communications, 16 (1), 1.
This publication has 56 references indexed in Scilit:
- Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosisBiomedicine & Pharmacotherapy, 2023
- Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]Ga-FAPI-04European Journal of Nuclear Medicine and Molecular Imaging, 2022
- Live and let die: TB control by enhancing apoptosisImmunity, 2021
- Macrophage and neutrophil death programs differentially confer resistance to tuberculosisImmunity, 2021
- Caspase-Based PET for Evaluating Pro-Apoptotic Treatments in a Tuberculosis Mouse ModelMolecular Imaging and Biology, 2020
- Drug-Induced Thrombocytopenia Secondary to Commonly Used Antibiotics in Total Joint ArthroplastyArthroplasty Today, 2020
- Automated GMP Synthesis of [18F]ICMT-11 for In Vivo Imaging of Caspase-3 ActivityNuclear Medicine and Biology, 2012
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosisHuman Pathology, 2006
- Monoclonal Antibody EBM11 (Anti-CD68) Discriminates between Dendritic Cells and Macrophages after Short-Term CultureImmunobiology, 1991